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Abstract Congenital disorders of the hepatic portal vas-
culature are rare in man but occur frequently in certain dog
breeds. In dogs, there are two main subtypes: intrahepatic
portosystemic shunts, which are considered to stem from
defective closure of the embryonic ductus venosus, and
extrahepatic shunts, which connect the splanchnic vascular
system with the vena cava or vena azygos. Both subtypes
result in nearly complete bypass of the liver by the portal
blood flow. In both subtypes the development of the
smaller branches of the portal vein tree in the liver is
impaired and terminal branches delivering portal blood to
the liver lobules are often lacking. The clinical signs are
due to poor liver growth, development, and function.
Patency of the ductus venosus seems to be a digenic trait in
Irish wolfhounds, whereas Cairn terriers with extrahepatic
portosystemic shunts display a more complex inheritance.
The genes involved in these disorders cannot be identified
with the sporadic human cases, but in dogs, the genome-
wide study of the extrahepatic form is at an advanced stage.
The canine disease may lead to the identification of novel
genes and pathways cooperating in growth and develop-
ment of the hepatic portal vein tree. The same pathways
likely regulate the development of the vascular system of
regenerating livers during liver diseases such as hepatitis
and cirrhosis. Therefore, the identification of these
molecular pathways may provide a basis for future prore-
generative intervention.
Congenital portosystemic shunts and associated liver
dysfunctions
Maintenance of liver mass and function is provided mostly
by hepatic perfusion, especially by the quantity and quality
of portal blood (van den Ingh et al. 1995). Normally, the
abdominal organs connected to the splanchnic vascular bed
(gastrointestinal tract, pancreas, and spleen) supply their
efflux blood to the portal vein. Portal blood delivers toxins,
nutrients, and bacteria absorbed from the intestine to the
liver. In addition, it contains specific hepatotrophic factors
like insulin, insulin-like growth factors, glucagon, and
hepatocyte growth factor (van den Ingh et al. 1995), and
carries 50% of the oxygen supply to the liver (Nelson et al.
2005).
Congenital portosystemic shunts (CPSS) are abnormal
vascular connections made during embryonic development,
which connect the portal vein directly to the vena cava or
vena (hemi)azygos. Portal blood thus bypasses the liver
and its functional units, the liver lobules (Vulgamott 1985;
Winkler et al. 2003). Because of the importance of portal
blood for the liver, portosystemic shunting has severe
impact on the homeostasis and well-being of the organism.
First, there is severely impaired liver growth and atrophy of
the remaining hepatocytes, leading to reduced hepatic
functions (Allen et al. 1999; Franchi-Abella et al. 2010;
Uchino et al. 1999; Winkler et al. 2003). Second, due to
portosystemic shunting the important function of the
liver—to clear portal blood—cannot be performed so that
toxins and metabolites reach the systemic circulation in
high concentrations. Substances derived from the
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gastrointestinal tract and pancreas, like ammonia, aromatic
amino acids, absorbed bacteria and endotoxins, hormones,
and growth factors are not subjected to hepatic metabolism
or presented to the liver (Nelson et al. 2005; Vulgamott
1985; Winkler et al. 2003). A major consequence is that the
brain is exposed to neurotoxins, resulting in hepatic
encephalopathy and eventually death (Martin 1993). The
biochemical features and the associated clinical signs are
similar between dogs and humans with congenital porto-
systemic shunts. In addition, to a large extent these are
similar to those seen in advanced chronic progressive liver
disease with fibrosis and cirrhosis. The main difference
between chronic progressive liver disease and congenital
portosystemic shunts is that the first group has portal
hypertension, which is absent in the congenital diseases.
Congenital portosystemic shunts can be divided roughly
into two main subtypes: intrahepatic (IHPSS) and extra-
hepatic shunts (EHPSS) (van den Ingh et al. 1995) (Fig. 1).
Although the genetic basis of CPSS in dogs is not clear yet,
many authors have demonstrated that congenital shunts are
more frequently diagnosed in purebred dogs and that a
number of breeds are predisposed to it (Hunt 2004; Tobias
2003), which indicates an inherited basis for this disease
(Meyer and Rothuizen 1991; van Straten et al. 2005). An
equal frequency of affected males and females was gen-
erally reported (Hunt 2004; van Straten et al. 2005). In
addition, EHPSS and IHPSS were very rarely seen in the
same breed (Hunt 2004; Krotscheck et al. 2007; Martin
1993; Tobias and Rohrbach 2003; Vulgamott 1985;
Winkler et al. 2003). Intrahepatic shunts were diagnosed
mainly in large dog breeds and extrahepatic shunts in the
smaller and toy breeds (Tobias and Rohrbach 2003; Tisdall
et al. 1994). CPSS in humans has been classified as being a
rare disease (Stringer 2008).
Congenital portosystemic shunts in man
and comparison with dogs
The same subtypes of intrahepatic and extrahepatic shunts
which are known in dogs have been described in humans.
From several literature reviews and case reports, the dis-
ease appears to be more prevalent in the Japanese popu-
lation. In total, there have been 173 human cases of EHPSS
reported (Caruso et al. 2010; Franchi-Abella et al. 2010;
Kobayashi et al. 2010; Konstas et al. 2010; Lautz et al.
2011; Newman et al. 2010; Ohno et al. 2008) and 89
human cases of IHPSS (Ferrero et al. 2010; Franchi-Abella
et al. 2010; Kamimatsuse et al. 2010; Konstas et al. 2010;
Ohno et al. 2008; Schierz et al. 2011; Stringer 2008; Tsai
et al. 2009; Uchino et al. 1999; Yoshimoto et al. 2004). In
human EHPSS, a classification has been made based on the
presence or absence of portal blood flow (Abernethy 1793).
Doppler ultrasound measurement of portal flow to the liver
proximal to the diversion of the shunting vessel has shown
that in dogs as well, cases with and cases without hepato-
petal blood flow do exist. Some affected dogs even have a
reversed hepatofugal portal blood flow away from the liver
(Szatmari et al. 2004a, c).
The histological features of the liver are identical in
humans and dogs with intrahepatic or extrahepatic porto-
systemic shunt. The findings include absence of portal
veins in small portal tracts, absent or hypoplastic portal
veins in medium-sized and larger portal tracts, tortuosity,
increased number and hypertrophy of arterioles in the
portal areas, and atrophy of hepatocytes (Baade et al. 2006;
Cullen et al. 2006; Lisovsky et al. 2011).
With respect to clinical presentation and methods to
diagnose the disease, there are no essential differences
between man and dog. The most prominent clinical signs
Fig. 1 Overview of the anatomy of a normal liver and of livers with
intra- and extrahepatic portosystemic shunts. a No connection of
blood vessels in the liver is seen within a normal liver resulting in a
blood flow through the hepatic sinusoids. b In case of PSS, blood
bypasses the liver sinusoids and is therefore not subjected to hepatic
metabolism. The intrahepatic shunt represents an abnormal connec-
tion of the portal vein with the systemic circulation, which is seen
inside the liver. c In the case of an extrahepatic shunt, the aberrant
connection is located outside the liver
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relate to brain dysfunction caused by hepatic encephalop-
athy in man (Ali et al. 2010; Alonso-Gamarra et al. 2011;
Murray et al. 2003) and dog (Maddison 1992). This syn-
drome is caused by neurotoxins bypassing the liver and the
blood brain barrier. The pathogenesis of the encephalopa-
thy is multifactorial in both species, but hyperammonemia
is a common major factor. In man and in dogs the severe
brain dysfunctions caused by hepatic encephalopathy are
transient and can be completely resolved upon successful
surgical closure of the congenital shunt (Alonso-Gamarra
et al. 2011; Hunt 2004; Kummeling et al. 2004).
Phenotyping
Dogs can be diagnosed starting at 6 weeks of age.
A globally used screening method measures increased
pre- and postprandial serum bile acid levels (Kerr and
van Doorn 1999). This test, however, gives abnormal
results for many different liver diseases and is sensitive,
but not specific, for congenital and acquired portosys-
temic shunting (Gerritzen-Bruning et al. 2006). Alterna-
tively, screening can be performed by measuring basal
plasma ammonia levels (Meyer et al. 1995; Sterczer et al.
1999; van Steenbeek et al. 2009). In Irish wolfhounds,
however, a congenital urea cycle enzyme deficiency may
also cause hyperammonemia (Zandvliet and Rothuizen
2007). In all other dog breeds, like in humans, the fasting
blood ammonia concentration and the rectal ammonia
tolerance test are the most sensitive and specific tools to
detect portosystemic shunting (Gerritzen-Bruning et al.
2006). In all cases, the diagnosis of the shunt and the
precise subtype has to be confirmed by direct demon-
stration of the shunting vessel. This can be achieved by
ultrasonography, computed tomography, or surgery
(Bertolini 2010; Szatmari et al. 2004b). The diagnostic
criteria used in veterinary and human medicine are
essentially identical. Hepatic encephalopathy, increased
plasma ammonia concentrations, and a decreased
ammonia tolerance indicate the likelihood of portosys-
temic shunting. The diagnosis in both species is con-
firmed and the subtype of the shunt is assessed with
ultrasonography or computed tomography (Alonso-Gam-
arra et al. 2011; Bertolini 2010; Szatmari et al. 2004b).
The use of a plasma bile acid measurement as a liver
function test, which is also used in the diagnostic pro-
cedure in veterinary medicine, is rarely used in human
medicine. This reflects a difference in established tradi-
tions between the two professions rather than a difference
between the types of shunts in man and dog.
Canine intrahepatic portosystemic shunt
An intrahepatic portosystemic shunt (IHPSS) is caused by
incomplete closure of the ductus venosus. The ductus
venosus is an embryonic vessel connecting the vena porta
with the vena cava, ensuring blood flow from the placenta
directly to vital organs without traversing liver sinusoids.
This vessel should close within the first few days after
birth. The moment of closure slightly fluctuates between
species (Lohse and Suter 1977). In dogs, the closure occurs
within 6–9 days (Lamb and Burton 2004). IHPSS is diag-
nosed almost exclusively in large-sized purebred dogs
(Hunt 2004; Rothuizen and van den Ingh 1982) and a
predisposition to IHPSS is suggested for Irish wolfhounds
(Kerr and van Doorn 1999; Meyer et al. 1995), Australian
Cattle dogs (Tisdall et al. 1994), Old English Sheepdogs
(Lamb and White 1998), and Labrador and Golden
retrievers (Tobias and Rohrbach 2003; van den Ingh et al.
1995). The shunt can be anatomically positioned at the left
or right side or centrally in the liver. Epidemiologic factors
influencing the position of the shunt have been surveyed
using case reports from the United States and Australia.
Significant association was found between IHPSS location
and country of origin (P = 0.048), breed (P = 0.025), and
sex (P = 0.016) (Krotscheck et al. 2007).
Heritability of IHPSS in Irish wolfhounds
The clear familial distribution for IHPSS in Irish wolf-
hounds indicates a hereditary basis (Meyer et al. 1995;
Ubbink et al. 1998). Between 1984 and 1992 the entire
Dutch Irish wolfhound population was screened for IHPSS
by measuring ammonia levels in blood and performing
subsequent ultrasonography on dogs with hyperammone-
mia. The observed incidence increased over the years
concomitant with increased inbreeding (Meyer et al. 1995).
A litter of Irish wolfhounds was presented to the Utrecht
University Clinic for Companion Animals for screening of
IHPSS. Both parents were unaffected, and their offspring
consisted of three affected and three unaffected dogs. We
studied the mode of inheritance by test matings between an
affected sire and two affected bitches after surgery and
maturation. The matings resulted in one litter of 5 affecteds
only and a litter of 11, with 5 affected and 6 unaffected
pups (Fig. 2). The unaffected offspring in the second litter
minimizes the possibility of a simple monogenic recessive
disorder. The presence of both left- and right-divisional
IHPSS suggests that the position is not genetically deter-
mined. The results indicate a genetic background with
possibly a digenic mode of inheritance (van Steenbeek
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et al. 2009). In our model, two loci interact to cause the
phenotype; at least three of the four alleles at the loci
would be mutant in affected dogs.
Canine extrahepatic portosystemic shunt
Whereas intrahepatic shunts are derived from pre-existing
embryonic connections, extrahepatic shunts must be con-
sidered as developmental anomalies. They represent
abnormal functional communication between the embry-
onic vitelline veins, which form the entire extrahepatic
portal system, and the cardinal venous system, which
contributes to all nonportal abdominal veins. This con-
nection results in a shunting vessel between the portal vein
or its contributors, such as the left gastric, splenic, mes-
enteric veins, or the gastroduodenal vein, and the caudal
vena cava or (hemi)azygos vein. Because the extrahepatic
portal vein develops from different parts of the vitelline
vein, and the vena cava and vena (hemi)azygos develop
from the embryonic cardinal vein, connections between the
cardinal and vitelline systems could not occur during any
phase of embryonic development (Payne et al. 1990).
Extrahepatic shunts occur in small dog breeds with a
predisposition in Cairn terriers (van Straten et al. 2005),
Yorkshire terriers (Tobias 2003; Tobias and Rohrbach
2003), Jack Russell terriers (Hunt 2004), Dachshunds (van
den Ingh et al. 1995), miniature schnauzers, Havanese,
Dandie Dinmont terriers (Tobias and Rohrbach 2003), and
Maltese (Tisdall et al. 1994).
Heritability of EHPSS in breeds of small dogs
A pedigree analysis of affected Cairn terriers born in The
Netherlands between 1990 and 2001 was performed to
study the genetics of EHPSS (van Straten et al. 2005).
A total of 6,367 pups were screened for shunts by measuring
venous ammonia concentrations at an age of 6 weeks.
Prevalences of 1.9–5.9% in three breeding lines were sig-
nificantly higher than the prevalence in the entire population
(0.58%), indicating a hereditary basis for this disease. Three
test matings were performed (Fig. 3). A successfully oper-
ated on female was mated with her unaffected father, an
affected son, and an unrelated affected male. Four of the 19
pups (21%) born from these matings were affected, provid-
ing further evidence that EHPSS is a genetic disorder. The
mode of inheritance is most likely polygenic and there seems
to be no sex effect (van Straten et al. 2005).
EHPSS can be classified in two subtypes: porta cava and
porta (hemi)azygos shunts. We have surveyed a large
number of cases (F. G. van Steenbeek, unpublished) and
found that both subtypes occur in all ten predisposed
breeds. On average, 23% connected with the vena
(hemi)azygos and 67% connected with the vena cava. The
presence of both types in all predisposed breed populations
Fig. 2 Pedigree of test matings of Irish wolfhounds with intrahepatic
shunt. An affected male was mated with two affected sisters. Squares
represent males, circles represent females. Solid symbols are affected
dogs and open symbols represent unaffected pups. Pups with uncertain
phenotypes are filled gray (reprinted with permission from John
Wiley and Sons; van Steenbeek et al. 2009)
Fig. 3 Pedigree of test matings with Cairn terriers with extrahepatic
shunt. An affected female (#9) was used three times, with her
unaffected father (#1), with her affected son (#21), and with an
unrelated affected male (#10). Squares represent males, circles
represent females. Solid symbols are affected dogs and open symbols
are healthy dogs (reprinted with permission from John Wiley and
Sons; van Straten et al. 2005)
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indicated a common genetic basis. The erroneous devel-
opment of the portosystemic connection between the
vitelline system and the vena cava or the vena
(hemi)azygos is most likely due to modulating factors at
specific time points during embryogenesis. The cava and
azygos veins are formed through several transformations of
the cardinal system (Payne et al. 1990).
Molecular genetic studies in our lab support the above
conclusions (F. G. van Steenbeek, unpublished). A gen-
ome-wide association study (GWAS) performed on Cairn
terriers resulted in three genomic regions strongly associ-
ated with EHPSS.
Candidate genes for congenital portosystemic shunts
Serendipitously, a mouse model was found that had an
intrahepatic shunt as seen in breeds of large dogs and in
man. This knockout mouse is homozygous for a deletion in
the aryl hydrocarbon receptor gene (AHR) (Lahvis et al.
2000). More recently, it was demonstrated that AHR sig-
naling in vascular endothelial cells is necessary for devel-
opmental closure of the ductus venosus. In contrast, AHR
signaling in hepatocytes is necessary to generate detoxi-
fying responses to dioxin exposure of the liver (Walisser
et al. 2005). AHR activates transcription of several cyto-
chrome P-450 subtype genes (Fig. 4) by forming a het-
erodimer with aryl hydrocarbon receptor nuclear
translocator [ARNT, also known as hypoxia-inducible
factor 1, beta subunit (HIF1B)) (Mimura and Fujii-Kuriy-
ama 2003). A unique cytochrome P-450 system functions
in the closure of the ductus venosus by its contractile effect
on the sphincter region in lambs (Adeagbo et al. 1990).
Which cytochrome P-450 subtype is responsible for this
contraction is still to be determined but CYP1A1 and
CYP1A2 were recently excluded (Nukaya et al. 2009).
ARNT is known for its role in angiogenesis under
hypoxia when it dimerizes with hypoxia inducible factor 1a
(HIF1A). Under hypoxic conditions, ARNT regulates
hypoxia-activated transcription in hepatocytes (Wood et al.
1996). ARNT-/- mouse embryos die in utero around
E10.5 due to extreme vascular defects (Maltepe et al.
1997). This impaired vascularization appears to be affected
by decreased expression of vascular endothelial growth
factor A (VEGFA). Activation of endothelial VEGFA
combined with inactivation of stromal transforming growth
factor-b was reported as being essential for AHR-mediated
angiogenesis (Roman et al. 2009), suggesting an interac-
tion between the AHR pathway and the HIF1A pathway.
Hypomorphic ARNT knockout mice appeared to display
identical phenotypical alterations as those of AHR knock-
out mice (Walisser et al. 2004). When a hepatocyte-specific
deletion of ARNT was applied, no shunting was observed;
hence, hepatocyte ARNT does not function in AHR-med-
iated hepatovascular development (Nukaya et al. 2010b).
Another protein that has a central role in both pathways
is heat shock protein 90 kDa alpha (cytosolic), class A
member 1 (HSP90AA1). HSP90AA1 was found to form a
cytosolic complex in hepatocytes with AHR (Perdew
1988), but it also appears to be an essential regulator in
HIF1A activation (Minet et al. 1999). Therefore,
HSP90AA1 could very well be the gene connecting AHR
with vascularization.
Aryl hydrocarbon receptor interacting protein (AIP) was
also found to play an important role in closure of the ductus
venosus. Construction of AIP (-/-) mice resulted in 83%
of the mice having intrahepatic shunting (Lin et al. 2008).
Hepatocyte-specific knockout mice showed that AIP has an
important role in the maintenance of cytosolic AHR levels
as well as in regulation of both CYP1B1 and the aryl
hydrocarbon receptor repressor. Striking though was that
CYP1A1 and CYP1A2 expression was not altered, sug-
gesting the presence of other AHR-responsive genes
(Nukaya et al. 2010a).
The AHR pathway is a strong candidate pathway for
involvement in canine and human IHPSS. In mice, all
homozygous AHR knockouts have IHPSS, whereas the
mode of inheritance in dogs is expected to be more com-
plex. In addition, the mouse model has quite a complex
phenotype, with multiorgan lesions that do not occur in
dogs or humans with IHPSS.
Closure of the ductus arteriosus, the fetal shunt con-
necting the pulmonary artery with the aorta that allows
blood to bypass the unexpanded lungs, is physiologically
comparable to closure of the ductus venosus in the liver.
Closure of the ductus arteriosus appears to be mediated by
the cytochrome P-450 gene CYP3A13 and the gene coding
Fig. 4 The relationship between the AHR pathway and the HIF1A
pathway. Both pathways share ARNT and HSP90AA1 as key
regulators
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for endothelin-1 (Baragatti et al. 2011). These findings
could correspond with a model of inheritance of defective
vessel closures involving a low number of genes.
In summary, the above genes and pathways have been
shown to be involved in IHPSS in mice and should be
considered important candidates for the human and canine
variants, but their role remains to be elucidated.
General medical relevance of genes and pathways
causing portosystemic shunts
Congenital forms of portosystemic shunt in children are
rare, with only 173 reported cases. Therefore, it is unlikely
that the molecular basis can be elucidated by study of
human cases. As illustrated above, purebred dogs display
the same types of congenital portosystemic shunts as seen
in man, with the same consequences with respect to clinical
signs, pathophysiology, and liver pathology. The inbreed-
ing of dog populations has led to an increased incidence of
genetic diseases which remained incidental in the pan-
mictic human populations. The complex genetic back-
ground of portosystemic shunts may well be unraveled in
dogs. This may not only reveal new genes and pathways
involved in vascular embryogenesis, but also important
candidate genes for the human forms of the disease. The
role of the candidate genes for the intrahepatic congenital
shunts discussed above could also become clear.
The importance of these genes and pathways may,
however, be much broader. Chronic progressive liver dis-
ease is a frequent and important health problem in man and
dog. Recent studies have shown that the pathogenetic
pathways of chronic fibrotic liver disease leading to cir-
rhosis are identical in man and dog (Ijzer et al. 2010;
Schotanus et al. 2009; Spee et al. 2007). Chronic liver
diseases are characterized by progressive fibrosis, ulti-
mately leading to dissection of the normal lobular structure
of the liver and ending in irreversible cirrhosis (Calvaruso
et al. 2008; Matsuzaki 2009; Thenappan et al. 2010; Torok
2008; Spee et al. 2006). Nowadays, the only possible
treatment is liver transplantation. Apart from fibrosis,
progression of these diseases is characterized by decreased
regeneration to compensate for the concomitant loss of
functional liver epithelium. The normally huge capacity of
the liver to regenerate by expansion of the hepatocyte
compartment becomes lost in chronic fibrotic disease,
regardless of the etiology (Hartmann et al. 2011; Nakajima
et al. 2006; Wege and Brummendorf 2007; Wege et al.
2003; Wiemann et al. 2002). This is in part compensated
for by adult stem cell activation, but this safeguard is
usually too small and occurs too late (Fausto 2004; Ijzer
et al. 2010; Roskams et al. 2003; Schotanus et al. 2009;
Spee et al. 2010). The third component of chronic
deterioration of liver function in progressive liver disease is
the ongoing impairment of portal liver perfusion (Fernan-
dez et al. 2009; Treiber et al. 2005; Yokoyama et al. 2007).
The triangle of lost regeneration, fibrosis leading to cir-
rhosis, and impaired vascularization determines the vicious
cycle of chronic progressive liver disease ending in the
need for transplantation.
In both man and dog the presence of a congenital por-
tosystemic shunt, either intra- or extrahepatic, is associated
with deranged formation and growth of the smallest
intrahepatic branches of the portal vein tree. In the veter-
inary literature this has been referred to as portal vein
hypoplasia (van den Ingh et al. 1995; Zwingenberger and
Shofer 2007) or microvascular dysplasia (Allen et al.
1999). There is one case report of a dog with three con-
genital vascular malformations combined: congenital por-
tosystemic shunt, hypoplasia of the intrahepatic portal tree,
and intrahepatic arteriovenous fistula (Favier et al. 2004).
As described above, we have observed that the different
subtypes of congenital extrahepatic porta cava and porta
(hemi)azygos shunts exist in similar ratios in all affected
dog breeds. This indicates that a limited number of genes
regulate the complex formation of the splanchnic vascular
bed and associated portal venous system. It is anticipated
that elucidation of these genes and the associated pathways
will also give insight into the pathologic vascular
derangements that are an essential part of the pathogenesis
of chronic progressive liver disease. This may also provide
new ways to intervene in these presently incurable
diseases.
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